Outset Medical 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $33.6 million, up 14% year over year and 6% sequentially.
- Product revenue was $23.7 million, up 15% year over year; console revenue was $10.5 million, up 26%; consumable revenue was $13.2 million, up 8%; and service and other revenue was $9.9 million, up 12%.
- Recurring revenue, including consumables and service, was $23.1 million, up 10% year over year.
- Non-GAAP gross margin was 40.8%, up approximately 100 basis points year over year; product gross margin was 44.2%, down 150 basis points, and service and other gross margin was 32.4%, up 760 basis points.
- Third-quarter non-GAAP operating expenses were $24.2 million, with over 300 basis points of operating leverage; excluding approximately $1 million of bad debt expense, operating expenses increased 4% compared with revenue growth of 14%.
- Non-GAAP net loss was $12.9 million, compared with $12.4 million in the third quarter of last year.
- Outset ended the quarter with $140.7 million in cash, cash equivalents, short-term investments, and restricted cash; third-quarter cash use was $10.3 million.
- Outset reported 96% cumulative retention among parent customers that have purchased Tableau consoles since commercial launch, and its customer satisfaction score exceeded the healthcare benchmarks used by a third-party consulting firm.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Tina Jacobson, Head of Investor Relations.
Please go ahead. Good afternoon, everyone, and welcome to Outset Medical's third quarter 2026 earnings call.
Today's speakers are Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer. The company issued a news release after the close of the market today, which can be found in the investor section of outsetmedical.com. This call is being recorded and will be archived there as well. All forward-looking statements made during today's call are intended to be protected under the Private Securities Litigation Reform Act of 1995. Outset assumes no obligation to update these statements. For a list and description of the risks and uncertainties associated with the business, please refer to Outset's public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. I will now turn the call over to Leslie Trigg.
Good afternoon, everyone, and thank you for joining us. Our team executed well in the third quarter, delivering solid progress against our strategic priorities. Just as importantly, we continued doing the foundational work that is strengthening the business and aligning our teams to drive more predictable, profitable growth. I'm confident that these efforts are positioning Outset to capture the significant opportunity ahead. With that, I'll dive right into third quarter results, beginning with financial performance. Revenue of $33.6 million was up 14% year-over-year and up 6% sequentially. Each of our revenue line items contributed to growth, both year-over-year and sequentially. We were particularly encouraged to see console revenue growth up 26% year-over-year, driven by new and refreshed console sales.
In terms of recurring revenue, in addition to solid treatment volume, sales of our EMR offering are starting to ramp and grew 23% year-over-year. Ongoing operational initiatives improved non-GAAP gross margin, while expense discipline delivered significant operating expense leverage. Our clinical excellence team was busy again this quarter with a full lineup of new go-live implementations completed for new customers and existing customers expanding to new locations. Among those were four of the top 10 U.S. health systems. We draw on years of valuable experience to support hospitals as they transition from outsource to insource, starting with a detailed project plan customized to each hospital needs, then executing that plan through nurse training, physician education, and change management support. All of that requires well-oiled cross-functional execution, and our teams continue to deliver time and again.
Beyond implementation, our clinical excellence team members collaborate with customers to maximize Tablo's system-wide benefits, helping to identify the outcomes that matter most to each organization. Tablo's unique data ecosystem, now comprising more than 10 trillion data points, enables us to track and trend key performance indicators and regularly share the insights with customers. This ongoing collaboration engages clinical and corporate leaders across our larger health systems, demonstrating value, strengthening customer relationships, and creating a foundation for broader system-wide adoption. That level of commitment to delivering measurable benefits is translating into strong customer advocacy. In our recent voice of the customer assessment conducted by a third-party consulting firm, Outset achieved an overall customer satisfaction score that exceeded all of the consulting firm's healthcare benchmarks. The results also shed light on what customers value most about Tablo.
Survey respondents scored Tablo highly for timely dialysis that improves patient satisfaction, lower infrastructure burden and system costs, and simpler dialysis delivery through easier nurse training, mobility, and ease of use. These findings validate Tablo's differentiated clinical, economic, and operational value proposition and equip our sales team to position Tablo as a platform for system-wide impact. Additionally, we took an opportunity to analyze our customer retention rate over time. The data revealed that since commercial launch, cumulative retention among parent customers that have purchased Tablo consoles is 96%. We attribute this result not only to our technology, but to the holistic customer experience our team delivers across field service, clinical excellence, data analytics, EMR, and many other functions within Outset. Strong customer advocacy and high retention feeds all three of our forward console growth drivers: refresh sales, expansion sales, and new customer sales.
Our first significant refresh agreement, which was signed in Q2 with HCA, reinforced one of the nation's largest health systems' long-term commitment to Tablo, added meaningful contracted backlog and revenue visibility, and validated the refresh opportunity. Our sales team is actively engaged with additional large health systems whose consoles are nearing end of life, and we're encouraged by the progress. We believe we are well-positioned to build on this momentum across an estimated $150 million refresh opportunity. Expansion sales is another of our most compelling growth vectors. Existing customers know our team, understand the implementation process, and have firsthand experience with the benefits of insource dialysis, creating a clearer, lower-friction trajectory from individual site success to systemwide adoption. We have a great foundation to build on. For example, all 14 of the largest health systems by estimated console opportunity are already existing customers.
Additionally, Tablo is already being used in one or more facilities of roughly half of the top 100 largest IDNs. The expansion revenue opportunity is twofold. First, same-store sales growth, which means expanding Tablo's use within a given hospital site, such as moving from Tablo use outside of the ICU to ICU as well, or vice versa. Both cases involve the purchase of additional Tablo consoles and incremental treatment volume. The second expansion opportunity is extending Tablo into new hospital facilities within the health system network. In the third quarter, we closed deals across both of these expansion avenues. Leveraging the deep expertise of our new commercial leadership, we're evolving Outset's commercial model to ensure we are well-positioned to execute across all these fronts: refresh, expansion, and new customer console sales. For example, we are reducing territory sizes so our representatives can build deeper relationships aimed at accelerating pipeline conversion.
Additionally, we've realigned compensation incentives to ensure they help drive our commercial priorities while investing to reward performance and impact time to productivity. In parallel, we are expanding our capital sales team regionally and at the national account level to deepen executive-level relationships and translate our enviable roster of national contracts into broad system adoption. Across sales, marketing, clinical, service, and enterprise accounts, we're working as one Outset, aligning our teams around a shared goal: accelerating adoption and driving conversion. This work is underway at a time when the environment for insource dialysis is becoming increasingly favorable. Two weeks ago, the Department of Health and Human Services launched the Kidney Care National Plan, which builds on federal dialysis priorities elevated in 2019 by way of an executive order. The national plan calls for greater patient choice, expanded access to home dialysis, and initiatives to encourage adoption of new dialysis technologies.
It also emphasizes reducing barriers for new dialysis service entrants and aims to address practices that HHS believes limit competition and constrain physicians' ability to offer patients access to a broader range of treatment options and new devices. These priorities are central to Outset's mission to drive fundamental change in how dialysis is delivered. We're encouraged by HHS's commitment as it aligns with what Tablo is designed to make possible, empowering health systems to bring dialysis in-house while giving patients greater flexibility in where they choose to receive treatment. Over time, changes to market practices and new program initiatives could broaden patient access to home-based care and new home dialysis technologies such as Tablo. While implementation of the national plan will determine its ultimate impact, we view it as a powerful recognition of the need for change and a meaningful step toward a more competitive, innovative dialysis landscape.
We believe Outset is well-positioned to help lead that change, and we applaud HHS for advancing better care for dialysis patients. Beyond this new policy tailwind, the macro backdrop for Tablo is attractive. Health systems are under increasing pressure to reduce costs and elevate the quality of care. Dozens of abstracts and papers now validate the clinical and financial benefits of Tablo. We believe there is an exceptionally strong case for bringing dialysis in-house with a simple, data-rich, EMR-connected platform that gives health systems greater control over a critical service line. Tablo's opportunity to earn market share has never been more compelling. We recognize that we have significant work ahead, but Outset has a strong foundation for scale with the right people and the right technology, and we're excited about what lies ahead. With that, I will turn the call over to Renee.
Thank you, Leslie, and good afternoon, everyone. Total revenue in the third quarter was $33.6 million, up approximately 14% compared to the third quarter of last year. Product revenue was $23.7 million, up 15% compared to last year. Console revenue of $10.5 million grew 26% compared to last year, and consumable revenue of $13.2 million was up 8% year-over-year. Service and other revenue was $9.9 million, up 12% year-over-year. Recurring revenue, which includes consumables and service, was $23.1 million, an increase of 10% compared to last year. Turning next to the P&L, please refer to the tables in today's earnings release for a reconciliation of GAAP to non-GAAP measures. Third-quarter non-GAAP gross margin was 40.8%, up approximately 100 basis points compared to last year, and driven primarily by product cost improvements, reduced overhead, and service efficiencies.
Product gross margin was 44.2%, down 150 basis points compared to last year due to a higher mix of console sales within product revenue. Service and other gross margin was 32.4%, up 760 basis points compared to last year, as our attach rates for implementation and EMR software continue to expand. Overall, this performance reflects continued execution and keeps us on track toward our next milestone of a 50% company-wide gross margin. Moving to operating expenses, we delivered over 300 basis points of operating leverage. Third quarter non-GAAP operating expenses were $24.2 million. Excluding approximately $1 million related to bad debt expense, operating expenses increased only 4% compared to revenue growth of 14%. Non-GAAP net loss was $12.9 million compared to a non-GAAP net loss of $12.4 million in the third quarter of last year. Moving to the balance sheet.
We ended the quarter with $140.7 million in cash equivalents, short-term investments, and restricted cash. With ongoing expense discipline and working capital management, cash use was $10.3 million in the third quarter, putting us on track to use approximately $40 million for the full year. Turning to our guidance for 2026, we are reiterating full-year revenue guidance of $125 million-$130 million. We continue to expect full-year non-GAAP gross margin to be in the low 40% to mid-40% range, with a reminder that a higher mix of console sales could shift gross margin towards the lower end of that range. Our confidence in this outlook is supported by a strong commercial pipeline and contracted backlog related to the HCA refresh agreement. With that, I'll turn the call back over to Leslie.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
